GFRA2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1746652	0.60	5/20
SCHEMBL1747049	0.58	5/20
SCHEMBL1744666	0.53	4/20
SCHEMBL16844693	0.45	4/20
SCHEMBL1745124	0.52	1/20
SCHEMBL1746725	0.50	1/20
SCHEMBL12019248	0.48	1/20
SCHEMBL1745194	0.48	1/20
SCHEMBL8530467	0.46	1/20
SCHEMBL1746615	0.45	1/20
SCHEMBL1744681	0.44	1/20
SCHEMBL1744692	0.44	1/20
SCHEMBL1745225	0.44	1/20
SCHEMBL1746643	0.43	1/20
SCHEMBL31360588	0.43	1/20
SCHEMBL21142559	0.43	1/20
SCHEMBL21810402	0.43	1/20
SCHEMBL1747359	0.43	1/20
SCHEMBL1744684	0.42	1/20
SCHEMBL1744685	0.42	1/20

Clinical trials — most relevant to GFRA2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Valproate and Levocarnitine in Children With Spinal Muscular Atrophy	PHASE3	UNKNOWN
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision	PHASE3	COMPLETED
Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients	PHASE3	COMPLETED
Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Cilostazol in Parkinson's Disease	PHASE2	NOT_YET_RECRUITING
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment	PHASE2	COMPLETED
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	PHASE2	COMPLETED
Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome	PHASE1/PHASE2	COMPLETED
Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib	PHASE1/PHASE2	COMPLETED
GDNF in ideopathicParkinsons Disease	PHASE2	COMPLETED
Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome	PHASE1/PHASE2	COMPLETED
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease	PHASE2	COMPLETED
AAV2-GDNF for Advanced Parkinson s Disease	PHASE1	COMPLETED
GDNF Gene Therapy for Parkinson's Disease	PHASE1	ACTIVE_NOT_RECRUITING
Association of Urine BDNF and NGF With Lower Urinary System Parameters	nan	RECRUITING
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder	nan	UNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Cryopreservation of Prepubertal Testicular Tissue for Preservation of Fertility in Young Boys With Cancer	nan	RECRUITING
Regulation of Stem Spermatogonia in the Mature Testis	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Cord Blood Serum in the Treatment of Neuro-Degenerative Ophthalmic Diseases. 1-Glaucoma	nan	COMPLETED
Association of Brain Derived Neurotrophic Factor (BDNF) rs6265 Gene Polymorphism With Susceptibility to Epilepsy	nan	UNKNOWN
The Role of Epigenetic Modifications in Autism Spectrum Disorder	nan	UNKNOWN
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury	nan	COMPLETED
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GFRA2 binder may also engage these)

Protein	Name	Similarity
Q5RAD6	—	1.000	Q5RAD6 →
Q5E9X0	—	1.000	Q5E9X0 →
O08842	—	1.000	O08842 →
O13157	—	0.994	O13157 →
P97785	—	0.994	P97785 →
GFRA1	GDNF family receptor alpha-1	0.993	landscape →
Q62997	—	0.992	Q62997 →
O13156	—	0.988	O13156 →
O93512	—	0.971	O93512 →
Q05716	—	0.962	Q05716 →
P47879	—	0.961	P47879 →
Q6PCX7	—	0.961	Q6PCX7 →
IGFBP4	Insulin-like growth factor-binding protein 4	0.961	landscape →
P20959	—	0.960	P20959 →
P21744	—	0.959	P21744 →
P24854	—	0.957	P24854 →
O13097	—	0.956	O13097 →
Q28893	—	0.956	Q28893 →
Q80UG6	—	0.956	Q80UG6 →
Q91590	—	0.956	Q91590 →
Q9Z0J1	—	0.956	Q9Z0J1 →
Q9QYV1	—	0.955	Q9QYV1 →
Q8C985	—	0.955	Q8C985 →
P0DJQ9	—	0.955	P0DJQ9 →
Q9N0A6	—	0.955	Q9N0A6 →
D4A6L0	—	0.955	D4A6L0 →
Q68US5	—	0.954	Q68US5 →
O95156	—	0.954	O95156 →
Q96B86	—	0.954	Q96B86 →
IGFBP3	Insulin-like growth factor-binding protein 3	0.954	landscape →